The Latest Research News

Hypertension treatment capacity in India by increased workforce, greater task-sharing, and extended prescription period: A modelling study

Lancet: Southeast Asia, March 01, 2023 The worldwide control rate for hypertension is dismal. An inadequate number of physicians to treat patients with hypertension is one key obstacle. Innovative health system approaches such as delegation of basic tasks to non-physician health workers (task-sharing) might alleviate this problem. Massive scale up of population-wide hypertension management is especially important for low- and middle-income countries such as India.

A Message From the Next Generation: I Believe in You—Take Control of Your Health

JACC: Advances, January 11, 2023 South Asian individuals (ancestry from Bhutan, Bangladesh, India, the Maldives, Nepal, Pakistan, and Sri Lanka) carry a disproportionately higher burden of atherosclerotic cardiovascular disease (ASCVD) and proportional mortality from ischemic heart disease when compared with other racial and ethnic groups.

Effect of hybrid immunity, school reopening, and the Omicron variant on the trajectory of the COVID-19 epidemic in India: a modelling study

Lancet: Southeast Asia, October 13, 2022 The course of the COVID-19 pandemic has been driven by several dynamic behavioral, immunological, and viral factors. We used mathematical modeling to explore how the concurrent reopening of schools, increasing levels of hybrid immunity, and the emergence of the Omicron variant affected the trajectory of the pandemic in India, using Andhra Pradesh (pop: 53 million) as an exemplar Indian state.

Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel

The Lancet, October 11, 2022 New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in developing tuberculosis vaccines for people with HIV, a series of symposia was held that posed six framing questions to a panel of international experts: What is the use case or rationale for developing tuberculosis vaccines? What is the landscape of tuberculosis vaccines? Which vaccine candidates should be prioritised? What are the tuberculosis vaccine trial design considerations? What is the role of immunological correlates of protection? What are the gaps in preclinical models for studying tuberculosis vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing tuberculosis vaccine development and the prioritisation of clinical trials for inclusion of people with HIV.

Faculty Receive Grant to Narrow Health Equity Gap in Chandigarh, India

Bloomberg School of Public Health, August 09, 2022 Ligia Paina, PhD ’14, MHS ‘08, an assistant professor in the Department of International Health’s Health Systems Program at the Johns Hopkins Bloomberg School of Public Health, and her co-PI Meng Zhu, PhD, MS, a professor at the Johns Hopkins Carey Business School, were awarded an Impact Grant from the Johns Hopkins Alliance for a Healthier World for their work aimed at narrowing the health equity gap in urban slums in Chandigarh, India.

The paradox of antimicrobial resistance in India

Fogarty International Center, June 15, 2022 India, home to one in every six people on the planet, has one of the highest rates of antimicrobial resistance (AMR) in the world. As a Fogarty Global Health Fellow, Dr. Matt Robinson worked in Pune, India, to characterize the burden of antimicrobial resistance among hospitalized patients with fever illnesses. “Fever is the most common reason why people in India seek medical care and we found that almost every patient hospitalized with fever received antibiotics—despite mosquito-borne diseases, which are not treated by antibiotics, being the cause of most of these illnesses,” said Robinson.

Alcohol reduction study in TB and HIV persons to commence in April in Pune

The Indian Express, March 26, 2022 US-based National Institutes of Health has funded a hybrid trial for alcohol reduction among people with TB and HIV in India (HATHI) that is set to begin in April in Pune. Johns Hopkins University in collaboration with Pune’s B J Government Medical College and Dr. D.Y. Patil Medical College, Hospital, and Research Center have developed a behavioral intervention to reduce alcohol use among TB/HIV patients.

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children

New England Journal of Medicine, March 10, 2022 Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen.

Study: Plasma Therapy Effective At Early Stage

The Times of India, December 26, 2021 Days after the World Health Organization (WHO) recommended against the use of plasma therapy for Covid-19, a multi-centre clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health has reiterated the treatment is beneficial indeed.

Johns Hopkins Receives Award for Antimicrobial Resistance Surveillance and Infection Control Partnership in India

Johns Hopkins India Institute, December 13, 2021 Drs. Matthew Robinson and Trish Simner of Johns Hopkins School of Medicine are collaborating with five Indian medical institutions with which JHU has longstanding research ties

News Release: CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases

US Centers for Disease Control and Prevention, December 07, 2021 These two new networks, paired with additional short-term research projects, will span more than 50 countries worldwide and build programs that focus on preventing infections in health care through proven infection control; build laboratory capacity to detect antimicrobial-resistant organisms in healthcare, the community, and environment; and develop new and innovative ways to more rapidly detect and respond to threats like AR and COVID-19.